| 2026-08-18 | Press release | PDF Version |
| 2026-08-18 | Press release | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-13 | Press release | PDF Version · Q2 2026 |
| 2026-08-13 | Press release | Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-12 | Deck | Corporate Presentation |
| 2026-07-17 | Press release | PDF Version |
| 2026-07-17 | Press release | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-17 | Press release | PDF Version |
| 2026-06-17 | Press release | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-11 | Press release | Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit |
| 2026-06-02 | Press release | PDF Version |
| 2026-06-02 | Press release | Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related D |
| 2026-05-28 | Press release | PDF Version |
| 2026-05-28 | Press release | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD |
| 2026-05-19 | Press release | PDF Version |
| 2026-05-19 | Press release | Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imm |
| 2026-05-18 | Press release | PDF Version |
| 2026-05-18 | Press release | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-13 | Press release | PDF Version |
| 2026-05-13 | Press release | PDF Version · Q1 2026 |
| 2026-05-13 | Press release | Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-13 | Press release | Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Ora |
| 2026-05-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-13 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-17 | Press release | PDF Version |
| 2026-04-17 | Press release | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-31 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-27 | Press release | PDF Version |
| 2026-03-27 | Press release | Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common S |
| 2026-03-26 | Press release | PDF Version |
| 2026-03-26 | Press release | Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock |
| 2026-03-16 | Press release | PDF Version |
| 2026-03-16 | Press release | PDF Version · Q4 2025 |
| 2026-03-16 | Press release | Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-03-16 | Press release | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-16 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-16 | Proxy | Definitive proxy statement |
| 2026-03-16 | 10-K | Annual report on Form 10-K, FY25 |